Cell Cycle Dynamics in Glioma Cancer Stem Cells

Qemo, Ingrid; Porter, Lisa A.

doi:10.1007/978-1-4939-8805-1_11

Cited by 5 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of GO analysis showed that the biological processes of DEGs were mainly concentrated in cell division, cell cycle process, cell cycle, DNA replication, regulation of cell cycle, and cell cycle checkpoint. Previous studies have reported that cell cycle processes and dysregulation of the mitotic cell cycle can play important roles in the occurrence or progression of cancers [33,34]. In addition, KEGG signaling pathway enrichment analysis suggested that these differential genes were mainly involved in cell cycle, progesterone-mediated oocyte maturation, oocyte meiosis, HTLV-I infection, and p53 signaling pathway.…”

Section: E919953-7mentioning

confidence: 89%

Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers

et al. 2020

View full text Add to dashboard Cite

Background:With the development of research on cancer genomics and microenvironment, a new era of oncology focusing on the complicated gene regulation of pan-cancer research and cancer immunotherapy is emerging. This study aimed to identify the common gene expression characteristics of multiple cancers -lung cancer, liver cancer, kidney cancer, cervical cancer, and breast cancer -and the potential therapeutic targets in public databases. Material/Methods:Gene expression analysis of GSE42568, GSE19188, GSE121248, GSE63514, and GSE66272 in the GEO database of multitype cancers revealed differentially expressed genes (DEGs). Then, GO analysis, KEGG function, and path enrichment analyses were performed. Hub-genes were identified by using the degree of association of protein interaction networks. Moreover, the expression of hub-genes in cancers was verified, and hub-generelated survival analysis was conducted. Finally, infiltration levels of tumor immune cells with related genes were explored. Results:We found 12 cross DEGs in the 5 databases (screening conditions: "adj p<0.05" and "logFC>2 or logFC<-2"). The biological processes of DEGs were mainly concentrated in cell division, regulation of chromosome segregation, nuclear division, cell cycle checkpoint, and mitotic nuclear division. Furthermore, 10 hub-genes were obtained using Cytoscape: TOP2A, ECT2, RRM2, ANLN, NEK2, ASPM, BUB1B, CDK1, DTL, and PRC1. The high expression levels of the 10 genes were associated with the poor survival of these multiple cancers, as well as ASPM, may be associated with immune cell infiltration. Conclusions:Analysis of the common DEGs of multiple cancers showed that 10 hub-genes, especially ASPM and CDK1, can become potential therapeutic targets. This study can serve as a reference to understand the characteristics of different cancers, design basket clinical trials, and create personalized treatments.

show abstract

Section: E919953-7mentioning

confidence: 89%

Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In other words, a precise understanding of the regulatory mechanisms governing the entry into and exit from the quiescent state is helpful for designing CSC-specific therapeutic strategies. A related article featured various facets of the cell-cycle dynamics in glioma CSCs . The idea was to determine the relative distribution of cells in the G 0 /G 1 , S, and G 2 /M phases of the cell cycle.…”

Section: Cell Cycle Epigenetics and Autophagy: Relevance To Cscsmentioning

confidence: 99%

“…A related article featured various facets of the cell-cycle dynamics in glioma CSCs. 29 The idea was to determine the relative distribution of cells in the G 0 /G 1 , S, and G 2 /M phases of the cell cycle. Surface markers CD133, CD15, and CD44 were used to identify cells with stem-like characters in established gliobastoma multiforme (GBM) cell lines and primary patient-derived tumor cell lines.…”

Section: Relevance To Cscsmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives

Kharkar

2020

J. Med. Chem.

View full text Add to dashboard Cite

Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity, reside in specialized tumor niches and are responsible for tumor maintenance, metastasis, therapy resistance, and tumor relapse. The new-age “hierarchical or CSC” model of tumor heterogeneity is based on the concept of eradicating CSCs to prevent tumor relapse and therapy resistance. Small-molecular entities and biologics acting on various stemness signaling pathways, surface markers, efflux transporters, or components of complex tumor microenvironment are under intense investigation as potential anti-CSC agents. In addition, smart nanotherapeutic tools have proved their utility in achieving CSC targeting. Several CSC inhibitors in clinical development have shown promise, either as mono- or combination therapy, in refractory and difficult-to-treat cancers. Clinical investigations with CSC marker follow-up as a measure of clinical efficacy are needed to turn the “hype” into the “hope” these new-age oncology therapeutics have to offer.

show abstract

“…However, Lui et al showed that CD44 expression identifies astrocyte-restricted precursor cells(Liu et al, 2004). In many other recent studies, CD44 has also been identified as a marker of astrocyte precursor cells(Cai et al, 2012;Malik et al, 2014;Naruse et al, 2013;Qemo and Porter, 2019). Thus, we suppose that the weak background of CD44 immunoreactivity in processes may indicate the stemness and precursor state of neoplastic astrocytes in DAs.…”

mentioning

confidence: 75%

Immunohistochemical classification of diffuse gliomas. Doctoral Thesis

Jakovlevs

View full text Add to dashboard Cite

Glioblastoma (GBM) is one of the most common and aggressive tumours of the central nervous system (CNS) and represents the highest grade (grade IV) of glioma. Despite the standard therapy with maximal possible resection, followed by radiotherapy and chemotherapy with temozolomide, the prognosis for GBM patients remains dismal. Identification and research of potential molecular and immunohistochemical markers will help to increase our awareness of critical molecular changes in tumorigenesis and increase the possibility of effective molecularly targeted therapy in future. New molecular and immunohistochemical prognostic markers can improve the treatment and even allow patients to be stratified into different prognostic groups, which will make the therapy more personalized. The aim of this research was to evaluate the morphological and immunohistochemical profile of gliomas ‒ glioblastoma (GBM) and diffuse astrocytoma (DA) ‒ as well as to evaluate the prognostic role of single immunohistochemical markers and the possibility of glioma subtyping by immunohistochemistry (IHC). This work was performed as a retrospective study that is based on the analysis of formalin-fixed, paraffin-embedded, surgically treated human glioma tissues. In the study, a comprehensive morphological and immunohistochemical evaluation was performed including analysis of eight immunohistochemical parameters and survival analysis by applying a wide range of descriptive and analytic statistic methods. A total of 172 patients with gliomas were enrolled in the research work, including 146 GBMs and 26 DAs. It was found that GBM patients were characterized by poor prognosis with a median survival time of 7.9 months, which is slightly below the survival rates reported in other countries. From the selected markers, the presence of isocitrate dehydrogenase 1 (IDH1) R132H mutation was the most significant prognostic factor of better survival in gliomas. However, in patients with DAs, high platelet-derived growth factor receptor alpha (PDGFRA) expression was also associated with significantly better survival. Some immunohistochemical markers, such as CD44, p21, p27, PDGFRA and Ki-67 proliferation, are grade-specific parameters in gliomas, thus CD44, Ki-67 and p21 are significantly upregulated; however, p27 and PDGFRA are downregulated in high-grade gliomas such as GBM. Surprisingly, gender-related differences were found in the expression of some immunohistochemical markers, such as p27, CD44 and Ki-67, in gliomas. In GBMs, cell cycle proteins, such as p53, p21 and p27, are involved in a variety of mechanisms that regulate proliferation and angiogenesis. A strong relationship was also found between the expression of PDGFRA and p53 in gliomas. In DAs, PDGFRA correlated inversely with CD44, p21 and microvascular density (MVD). Finally, it was found that subtyping of gliomas is possible by IHC using a limited number of markers – PDGFRA, p53, IDH1, R132H and CD44. In addition, the expression of CD44 was shown to be a reliable indicator of mesenchymal subtype in GBM, which has a worse response to radiotherapy.

show abstract

Cell Cycle Dynamics in Glioma Cancer Stem Cells

Cited by 5 publications

References 26 publications

Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers

Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers

Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives

Immunohistochemical classification of diffuse gliomas. Doctoral Thesis

Contact Info

Product

Resources

About